Pioneers of Tumour Immune Gene Therapy
MolMed S.p.A
MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel anticancer therapies.
Years of efforts and commitment led MolMed, established in 1996 as an academic spin-off, to be one of the leading international players in the promising field of gene and cell therapy, a pioneer in the area of tumour immune gene therapy, and an ideal partner for pharma and biotech companies in the field of hematopoietic stem cells transduction. These results represent the extent of the Company’s most profound value. Today MolMed’s commitment is making its research and development results available to the patient and to the market, thus satisfying still unmet therapeutic needs.